A nurse is caring for a client who has myasthenia gravis which has not responded to medication treatments. Which of the following surgeries can treat myasthenia gravis?

A. Splenectomy is not a standard treatment for myasthenia gravis. The spleen's role is primarily related to immune function and blood filtration rather than the pathophysiology of MG.
B. Thymectomy is a surgical procedure that involves the removal of the thymus gland. The thymus gland plays a role in the development and regulation of the immune system. In some cases of myasthenia gravis, especially in younger patients or those with thymoma (a tumor of the thymus gland), thymectomy can lead to improvement or remission of symptoms. This procedure is considered in cases where myasthenia gravis is refractory to medication or in cases associated with thymoma.
C. Appendectomy is the surgical removal of the appendix and is not a treatment for myasthenia gravis. The appendix is not implicated in the pathophysiology of MG.
D. Cholecystectomy is the surgical removal of the gallbladder and is performed for conditions related to the gallbladder, such as gallstones or inflammation. It is not indicated for the treatment of myasthenia gravis.

A. Dopamine is primarily associated with other neurodegenerative disorders such as Parkinson's disease, not Alzheimer's disease. In Alzheimer's disease, the focus is on changes related to beta-amyloid plaques and neurofibrillary tangles rather than alterations in dopamine levels.
B. Glial cells, including astrocytes and microglia, play a role in the brain's immune response and support of neurons. In Alzheimer's disease, there is evidence of increased activation and proliferation of glial cells in response to neuroinflammation and the presence of beta-amyloid plaques and neurofibrillary tangles. This reactive gliosis is a secondary response to the underlying pathology.
C. Glutamate is an excitatory neurotransmitter involved in various brain functions, including memory and learning. In Alzheimer's disease, there is evidence of dysregulation in glutamate metabolism and

signaling pathways. This dysregulation can lead to excitotoxicity, which contributes to neuronal damage and cell death seen in the disease.
D. Neurofibrillary tangles are one of the hallmark pathological features of Alzheimer's disease. These tangles are aggregates of hyperphosphorylated tau protein that accumulate inside neurons, disrupting their normal functioning and eventually leading to cell death. Neurofibrillary tangles, along with beta- amyloid plaques, contribute to the progressive cognitive decline observed in Alzheimer's disease.